Abstract
There is debate about what is the optimal treatment for operable stage I non-small cell lung cancer (NSCLC). Although surgery has been the standard of care for centuries, recent retrospective and prospective randomized studies indicated that stereotactic ablative radiotherapy (SABR) could be an option for this group of patients with similar survival and less toxicities. However, to change the standard of care, more studies are needed and participating ongoing larger randomized studies is the best approach to resolve this controversy.
Original language | English (US) |
---|---|
Pages (from-to) | 183-189 |
Number of pages | 7 |
Journal | Translational Lung Cancer Research |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1 2016 |
Keywords
- Non-small cell lung cancer (NSCLC)
- Stage I
- Stereotactic ablative radiotherapy (SABR)
- Stereotactic body radiotherapy (SBRT)
- Surgery
ASJC Scopus subject areas
- Oncology